Company profile
COLLEGIUM PHARMACEUTICAL, INC
NASDAQ:COLLBiotechnology: Pharmaceutical Preparations
Drug pipeline (5)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| DEXMETHYLPHENIDATE HYDROCHLORIDE | approved | — | 2 | approved |
| Oxycodone | approved | — | 0 | — |
| SERDEXMETHYLPHENIDATE CHLORIDE | approved | — | 0 | — |
| Tapentadol hydrochloride | approved | — | 0 | — |
| METHYLPHENIDATE HYDROCHLORIDE | phase1 | — | 6 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01685684 | phase3 | completed | 2012-08-01 | 2014-06-01 | Collegium Pharmaceutical, Inc. | Oxycodone DETERx™ Versus Placebo in Chronic Low Back Pain (CLBP) |
FDA applications (6)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 022304 | NDA | COLLEGIUM PHARMACEUTICAL INC | ||||
Loading… | ||||||
| NDA 200533 | NDA | COLLEGIUM PHARMACEUTICAL INC | ||||
Loading… | ||||||
| NDA 203794 | NDA | COLLEGIUM PHARMACEUTICAL INC | ||||
Loading… | ||||||
| NDA 208090 | NDA | COLLEGIUM PHARMACEUTICAL INC | ||||
Loading… | ||||||
| NDA 209311 | NDA | IRONSHORE PHARMACEUTICALS INC A WHOLLY OWNED SUB OF COLLEGIUM PHARMACEUTICAL INC | ||||
Loading… | ||||||